PIPELINE

Shaping Tomorrow with
Next-Gen Therapeutics
  • home
  • Pipeline
  • Oncology

Oncology

PMB298 (Candidate discovery) :
The 3rd generation immunotherapy

Third-generation cancer immunotherapy refers to the attempts targeting simultaneously immune checkpoints and the tumor immune microenvironment, with the goal of efficiently suppressing multiple aspects of negative immune regulation during immunotherapies.
Our third-generation immunotherapy is a small molecule designed to simultaneously inhibit two proteins that suppress anti-cancer immunity and generate immunosuppressive tumor microenvironment, respectively.
Therefore, the resulting candidates are expected to demonstrate the ability to enhance anticancer immunity and reprogram the immunosuppressive tumor microenvironment.

In fact, the lead compound in this project has shown efficacy in animal studies by activating CD8+T cells while suppressing Treg cells. As a result, it showed a higher CD8+T-cell/Treg-cell ratio than the anti-PD-L1 antibody.

Targets for Reprogramming
Tumor Microenvironment

Moiety for
reprogramming
TME
Moiety for
immune
boosting

Targets for Small Molecule
Immuno-therapeutics
Combination
Multiple molecules with own functions
They are distributed separately and thus each function may act in different places.
Multitargeting
Single molecule with multiple mechanisms
It is distributed uniquely, and its mechanisms act always in a same place.